BioNxt Achieves Milestone with Pilot Study for Contract Development Client

BioNxt Solutions Inc. is thrilled to announce the successful completion of a human pilot study for a top European-based generic drug company. BioNxt proudly developed an oral dissolvable narcotics product and managed a comparative bioavailability study to demonstrate its efficacy. This marks a major milestone in the company’s mission to revolutionize the pharmaceutical industry!

BioNxt is blazing a trail of development with a pipeline of in-house and contracted drug formulation programs, and is thrilled with the success of recent contract development products. This presents an unparalleled chance for BioNxt to expand its scope from drug development to commercial manufacturing as the in-house and contracted products move ever closer to commercialization. Hugh Rogers, CEO of BioNxt, is excited about the potential.

Vektor Pharma TF GmbH, a wholly owned subsidiary of BioNxt, is a German drug development and manufacturing company located in the district of Biberach, Baden-W├╝rttemberg, Germany. For over a decade, the company has been at the forefront of the design, testing and manufacture of non-invasive drug delivery systems, such as transdermal patches and sub-lingual strips, to deliver active pharmaceutical ingredients to treat pain and neurological conditions.

The global pharmaceutical drug delivery market is predicted to reach USD 2,047 billion by 2030, according to Precedence Research, with the market size valued at USD 1,525 billion in 2022.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience accelerator that is at the cutting edge of the next generation of drug formulations and delivery systems, diagnostic screening tests and active pharmaceutical production and evaluation.

Our precision transdermal and oral dissolvable drug formulations, rapid and cost effective infectious disease and oral health screening tests, and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications are paving the way for medical products to be approved and commercialized in European markets.

With research and development operations in North America and Europe, with a focus in Germany, BioNxt Solutions Inc. is leading the way in the medical industry.

Leave a Comment